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Clostridium difficile (C. difficile) infection is a leading cause of morbidity and mortality 
in the United States, making the infection a top public health priority. Early and accurate 
identification of disease is a critical factor in successful management, including clinical 
symptomology. The testing methods for C. difficile have improved in efficiency and 
sensitivity, which potentially causes over- or underprescribing behavior. Guided by the 
symbolic theory, the purpose of this study was to examine the association between C. 
difficile testing method by case year (2015 and 2018) and antibiotic treatment with the 
potential moderation of clinical symptoms. The secondary correlational analysis included 
patients admitted to a large suburban hospital with a positive test for C. difficile in 2015 
and 2018 (N = 509). The relationship between the study predictor (case year), dependent 
variable (antibiotic treatment), and moderator (symptom) was analyzed using binomial 
logistic regression. Antibiotics showed a significant association with the case year (OR = 
1.889) and no significant moderation with the addition of symptoms (OR = 1.303). 
Health care providers may find these findings useful in standardizing treatment of C. 
difficile through the implementation of additions to clinical algorithms, resulting in 
positive social change. Increased education, and policy, through antibiotic-resistant 
organism reduction, increased antimicrobial stewardship, and increased patient safety, 
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Section 1: Foundation of the Study and Literature Review 
Clostridium difficile (C. difficile) is a spore-forming bacillus that is acquired 
through orally ingesting the organism in the environment (Jump, 2013). The human 
intestinal system protects most people from the organism colonizing (Lawley & Walker, 
2013). Individuals who have had exposure to antibiotics such as Vancomycin are at risk 
for C. difficile infection due to the changes in the microbiota in the intestines producing 
symptomatic diarrhea (Isaac et al., 2017). The incidence of C. difficile in the United 
States among patients at least 1 year of age was 130 per 100,000 or 15,512 cases in 2017 
(Centers for Disease Control and Prevention [CDC], 2018). More than 50% (7,973) were 
hospital-associated due to a positive test at least 4 days after admission to a health care 
facility (CDC, 2019c, 2019d, 2020). The method used to identify C. difficile includes 
different testing methods with the result guiding, in part, the patient’s course of treatment 
(McDonald et al., 2018). Diagnostic stewardship is critical to the management, 
identification, and appropriate treatment of C. difficile infection (Rock et al., 2018).  
Background 
Nucleic Acid Amplification Test 
The nucleic acid amplification test (NAAT) is a sensitive and rapid test used to 
determine the presence or absence of C. difficile in a stool sample (Truong et al., 2017). 
The NAAT alone cannot distinguish between toxin negative and toxin positive C. difficile 
(Truong et al., 2017). The guidelines for testing indicate that NAAT is sufficient for 
diagnosis, but only in the presence of symptoms such as three or more liquid stools 
within 24 hours or fever or an increase in serum creatinine (McDonald et al., 2018). The 
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NAAT is not appropriate if other reasons for diarrhea have not been ruled out, such as the 
use of laxatives or recent colon surgery (McDonald et al., 2018). The use of the NAAT 
preliminarily identifies the possibility of C. difficile as one cause of diarrhea. However, it 
does not provide enough clinical evidence because the confirmatory toxin is not able to 
be identified with the NAAT (Quest Diagnostics, 2017). 
Two-Step Testing 
The two-step testing method was developed to identify stool specimens that were 
toxin negative and required further testing to rule out potential causes for diarrhea other 
than C. difficile (McDonald et al., 2018; Truong et al., 2017). The two-step method 
includes an antigen (glutamate dehydrogenase [GDH]) test and a toxin test to identify the 
presence of toxigenic C. difficile (Quest Diagnostics, 2017). If both tests are positive, 
then the sample is considered positive for toxigenic C. difficile, and the physician should 
treat accordingly (Quest Diagnostics, 2017). If the GDH is positive and the toxin is 
negative, then a tiebreaker (NAAT) must be completed to confirm the result (Quest 
Diagnostics, 2017). The result of the tiebreaker is used for treatment and determines the 
most effective patient treatment strategy (Quest Diagnostics, 2017) . If the GDH and 
toxin are negative, then the result is negative (Quest Diagnostics, 2017). The result used 
for treatment and reporting is the final answer from either the NAAT or the toxin from 
the two-step method.  
Reasons for Change 
The reasons for the change from a two-step algorithm to a single NAAT are 
twofold. First is the consideration of turnaround time for receiving results. The result of a 
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NAAT is available in less than an hour, while the two-step takes longer due to the 
increased number of steps involved to obtain accurate results (Quest Diagnostics, 2017). 
The other consideration is that the sensitivity is slightly less with the two-step versus the 
NAAT. The change from a single NAAT to the two-step is not due to concerns related to 
the capabilities of the testing procedures, but rather to the need to identify toxin-negative 
samples for discerning appropriate treatment methods. The NAAT cannot classify toxin 
status but can identify the presence or absence of C. difficile (Quest Diagnostics, 2017). 
The only scientific evidence-based method to isolate the presence of toxin is to use a 
toxin assay (Theiss, Balla, Ross, Francis, & Wojewoda, C.T, 2018) 
Treatment Methods 
Treatment of C. difficile depends on the level of the disease present and the status 
of a recurrent or initial episode of C. difficile (McDonald et al., 2018). Patients without 
symptoms of C. difficile, such as increased diarrhea (more than three episodes in 24 
hours), increase in white blood cells, fever, abdominal pain, or ileus, should not be 
treated (McDonald et al., 2018). Testing results should not be used without the clinical 
collaboration of symptomology (McDonald et al., 2018). If the patient’s clinical 
symptoms (with or without testing confirmation) are suspicious for C. difficile, then the 
patient should be started on an antibiotic (McDonald et al., 2018). The regimen should 
include vancomycin or fidaxomicin unless both are unavailable; then metronidazole is 
suitable for the first episode of nonsevere C. difficile (McDonald et al., 2018). Patients 
with recurrent C. difficile should be started immediately on vancomycin or fidaxomicin, 
and patients with fulminant C. difficile regardless of the number of episodes should be 
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started on vancomycin (McDonald et al., 2018). The inappropriate use of antibiotics for 
C. difficile is simultaneously related to current accepted clinical testing and treatment 
practices, and a lack of knowledge regarding patient outcomes over the long run when 
antibiotics are prescribed unnecessarily to treat a suspected diagnosis of C. difficile. 
Problem Statement 
Antibiotic resistance, recurrent C. difficile, and prolonged hospitalization are 
potential outcomes for patients identified with C. difficile in the hospital (CDC, 2019b); 
Rock et al., 2018). Patients with a positive C. difficile test result without clinical 
symptomology are at risk for inappropriate administration of antibiotics (Rock et al., 
2018). The Centers for Medicare and Medicaid Services instituted a requirement in 2013 
for all acute care facilities to report all laboratory-identified C. difficile to assist in 
holding administrators accountable through financial incentives for C. difficile infection 
avoidance (Medicare Program Hospital Inpatient Prospective Payment Systems for Acute 
Care Hospitals, 2017). Although patients are identified with a positive result of C. 
difficile, physicians are strongly encouraged to confirm the infectious status through toxin 
confirmation along with the presence of symptoms before prescribing treatment 
(Ooijevaar et al., 2018).  
One reason for the inappropriate treatment of C. difficile is the misclassification 
of the presence of nontoxigenic C. difficile as an indication of infection (Ooijevaar et al., 
2018). The identification of C. difficile using the NAAT from both symptomatic and 
asymptomatic patients is similar (Truong et al., 2017). A testing algorithm, including 
both the NAAT and toxin confirmation testing, is another useful option for health care 
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facilities to consider when identifying and attempting to distinguish between C. difficile 
infection and colonization to guide appropriate treatment decisions (Truong et al., 2017). 
Research is clear about the potential for the different testing methods to identify the 
presence of toxigenic C. difficile and the reason for using each type based on the needs of 
each facility (Ooijevaar et al., 2018). Many facilities have moved to the NAAT from a 
cost perspective resulting in faster available results with standard guidelines for antibiotic 
treatment (Amado, Bekker, Moshgriz, Keiser, & Siegel, 2016). However, the effect of a 
change from a single NAAT to a two-step algorithmic testing method with a moderating 
effect of patient symptomology upon antibiotic treatment is not well defined based on 
available literature. 
Purpose of the Study 
The purpose of this study was to examine the effect of changing from the NAAT 
to a two-step algorithm for the identification of C. difficile and the resultant prescribed 
treatment for hospitalized patients with a modifying presence of symptoms. A 
quantitative approach was used to address the gap regarding the relationship between the 
testing year (2015 and 2018), antibiotic prescribing (yes or no), and recognized patient 
symptomology (yes or no). The secondary de-identified patient data set, which included 
the testing year, results, and antibiotics prescribed, was examined for differences. The 
study was unique because it addressed moving from a specific testing method (NAAT) 
conducted during 2015 to a two-step method that included toxin identification during 
2018 (see Ooijevaar et al., 2018) along with the prescribing patterns, test results, and 
recognized symptomology cues (see McDonald et al., 2018).  
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Research Questions and Hypotheses 
RQ1: Is there a statistically significant association between the testing period 
(2015 and 2018) and antibiotic treatment (yes or no)? 
Ho1: There is not a statistically significant association between the testing period 
(2015 and 2018) and antibiotic treatment (yes or no). 
Ha1: There is a statistically significant association between the testing period 
(2015 and 2018) and antibiotic treatment (yes or no). 
RQ2: Does the presence of a recognized symptom (yes or no) moderate the 
relationship between the testing period (2015 and 2018) and antibiotic treatment (yes or 
no)? 
Ho2: The presence of a recognized symptom does not moderate the relationship 
between the testing period (2015 and 2018) and antibiotic treatment (yes or no). 
Ha2: The presence of a recognized symptom moderates the relationship between 
the testing period (2015 and 2018) and antibiotic treatment (yes or no). 
Theoretical Framework 
The framework applicable to this study was the symbolic interaction theory (see 
Goffman, 1967; Rose, 1962). The social interaction between the actor (physician) and the 
world (the hospital) is the primary focus that guides the interaction or treatment of the 
patient (see Goffman, 1967). The theory contains the following assumptions: (a) Humans 
interact in both physical and symbolic environments, (b) a person’s response to a 
symbolic communication is ascribed from learned behavior or meaning from others, and 
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(c) a person’s experience is used to assign meaning to the behavior of others (see 
Goffman, 1967; Rose, 1962).  
C. difficile infection diagnosis requires a physician to complete a complex 
decision-making process. The interactions or weighing by the physician of the particular 
tool used for testing, the patient’s symptoms, and the need to treat are interrelated (see 
Bobenchik, 2019). The physician’s decision to prescribe treatment is related to the 
outcome of the testing and the accepted behavior through symbolic interactions among 
physician peers within the facility. The present study focused on the interaction of the 
testing method and the physician’s decision to treat. The research questions were related 
to the theory in examining whether an association of symptoms is present as indicated 
when using NAAT alone when testing for C. difficile to determine the need for treatment.  
Nature of the Study 
The nature of the study was quantitative with a correlational design including 
secondary data from electronic medical records. The data set included records from 
January 1, 2015, through December 31, 2015, and January 1, 2018, through December 
31, 2018, from a large suburban health care facility with over 500 beds. All patients who 
tested for C. difficile at the acute care facility with a positive result were included in the 
analysis. The patient population under study included all ages and service status such as 
intensive care or medical ward. The predictor variable was the case year (2015 or 2018). 
The dependent variable was the treatment being prescribed (yes or no). The mediator 
variable was whether a recognized symptom of C. difficile was present (yes or no). 




According to the World Health Organization (2020), “patient safety is the absence 
of preventable harm to a patient during the process of health care and reduction of risk of 
unnecessary harm associated with health care to an acceptable minimum” (Patient safety 
section, para. 1). Health-care-associated C. difficile harmed almost 224,000 hospitalized 
patients in 2017 (CDC, 2019b). Correct identification of the disease is necessary to 
ensure proper treatment (Bobenchik, 2019). The emergence of antibiotic-resistant C. 
difficile is on the rise (CDC, 2018). The outcome of this study may increase awareness 
and knowledge surrounding the appropriateness of treatment based on the two-step 
testing results versus the treatments currently prescribed for NAAT results. Knowledge 
regarding appropriate treatment requires precise results to determine the difference 
between colonization and infection (Bobenchik, 2019). Testing methods and treatment 
guidelines have been addressed in multiple research outcomes and scientific societal 
guidelines (Bobenchik, 2019; Cho, Pardi, & Khanna., 2020; Crowell et al., 2017; 
McDonald et al., 2018). However, the effect of a change from the NAAT to two-step 
testing methods on prescribing patterns is not apparent (Ooijevaar et al., 2018; Truong et 
al., 2017). The original contribution of this research was in two areas. First was the 
review of following a counterintuitive path that requires two steps versus one step. 
Second was the contribution to the physicians with documentation to identify patterns of 
prescribing behavior among the population.  
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Positive Social Impact 
The identification of how prescribing patterns changed or did not change after the 
implementation of two-step testing was one way to inform professional practice and to 
identify appropriate or inappropriate antibiotic use. Inappropriate antibiotic use leads to 
infections with antibiotic-resistant organisms, such as vancomycin-resistant enterococcus 
(Isaac et al., 2017). One potential social outcome of the study was to increase awareness 
among health care providers regarding the effect of treatment for C. difficile clinical 
practice and the resultant impact on the antibiotic resistance problem that is prevalent in 
the United States (see Colman, Krockow, Chattoe-Brown, & Tarrant, 2019; McCullough, 
Rathbone, Parekh, Hoffmann, & Del Mar, 2015). If inappropriate antibiotic use is 
identified, hospital administrations and medical staff may review the results to determine 
better treatment algorithms.  
The physicians who practice at the study facility are part of the same primary 
group servicing multiple other facilities in the region. Sharing the clinical outcomes data 
from this study with local physicians, local hospital infectious disease departments, and 
local hospital administrators may improve testing and treatment outcomes within the 
local community. Also, there is a possibility that the results may be generalized to other 
populations, and that antibiotic-resistant cases may be minimized. 
The identification and correction of inappropriately prescribed antibiotics may 
positively affect patients, administrators, and providers. The benefits of decreasing the 
overuse and misuse of antibiotics can positively affect everyone, including patients and 
providers. For instance, patients who have nonmultidrug infections are less costly than 
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patients who have multidrug-resistant infections (Chen & Fu, 2018). One of the primary 
causes of C. difficile infection is the use of antibiotics; therefore, by reducing 
inappropriate antibiotic use regardless of the prescription reason, the overall burden of C. 
difficile may be reduced. In 2019, there were more than 2.8 million antibiotic-resistant 
infections worldwide (CDC, 2019a).  
Finally, C. difficile was responsible for 14,000 deaths and more than 200,000 
infections in 2019, making the organism one of the top priorities for prevention and 
control (CDC, 2019a). The ability to treat appropriately requires specific knowledge for 
identifying the disease under scrutiny (CDC, 2019c). The contribution of this doctoral 
project may be a local change in identifying the patterns of application or prescribing of 
antibiotic use for C. difficile, which may lead to a decrease in antibiotic use. The decrease 
in antibiotic use may lead to a reduction in multidrug-resistant organisms that expose 
staff and patients to an increased risk of infection (CDC, 2019c).  
Literature Search Strategy 
The doctoral project included a search for relevant literature from multiple 
databases. The search included CINAHL, Medline, PsycInfo, ScienceDirect, ProQuest, 
and Embase databases for peer-reviewed scholarly journal articles published during or 
after 2017. The initial search terms of c-diff or Clostridium difficile or C diff or c diff or c. 
diff or CDI and test or testing and symptoms or signs or characteristics or presentation or 
symptomatology resulted in 625 nonduplicative results. The search results were narrowed 
using the search terms toxic or toxicity or toxigenic or toxin, which resulted in 593 
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nonduplicative results. A final narrowing was conducted to include articles that met 
specific inclusion criteria. 
The inclusion criteria for the literature review included (a) relevance to the health 
care industry, (b) English language articles, (c) relevance to C. difficile testing or 
treatment, and (d) relevance to antibiotic use. Seminal works from as early as 1962 
related to the symbolic interaction theory were included in the study. Also, the literature 
review included six books and multiple internet-based subject-matter expert sources such 
as the CDC. The final literature review included 104 articles.  
Literature Review  
Unnecessary antibiotic use contributes to the increased prevalence of diarrheal 
episodes with longer episodic time frames and increased subsequent complications (Cho, 
et al., 2020). Patients with C. difficile are more likely to have taken third-generation 
cephalosporins for 3 or more days than those who do not have C. difficile (Lee et al., 
2019). The cause of C. difficile is unknown. However, the recognition of the symptoms 
that leads to testing has been well researched (Hematyar et al., 2020; Truong et al., 2017).  
Symptoms 
Symptoms of C. difficile include diarrhea with abdominal cramps, fever, 
increased serum creatinine, and increased white blood cell count in any combination 
(McDonald et al., 2018; Rock et al., 2018). Confirmation of the symptoms, along with a 
positive C. difficile test, is critical to the management of C. difficile (Cho et al., 2020; 
Crowell et al., 2017; Ooijevaar et al., 2018). The definition endorsed by health care 
facilities for diarrhea is three or more episodes of liquid stool that takes the shape of the 
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container, and fever is a temperature above 100.4 Fahrenheit (CDC, 2020; Quest 
Diagnostics, 2017). Abdominal cramps are subjective, and white blood cell count above 
the patient’s normal levels are considered symptomatic (McDonald et al., 2018; Rock et 
al., 2018). Although symptomatic carriers are more readily identified, consideration must 
be given to asymptomatic carriers who may develop the disease with symptoms during 
hospitalization (Kagan et al., 2017). 
Testing 
Testing methodologies include one or two tests to confirm the presence and 
toxigenic status of the patient’s sample. The specimen quality (liquid only) is vital for 
two reasons. If the NAAT is used, part of the process is to ensure only appropriate liquid 
diarrheal specimens are tested because the test detects regardless of the sample type 
(Goret et al., 2018). If an NAAT is used and the sample is not meeting diarrheal criteria, 
then treatment may be instituted on asymptomatic patients (Goret et al., 2018). The issue 
becomes whether the sample is toxigenic and whether the sample is indicative of a patient 
with a current symptomatic disease (Kagan et al., 2017). One way to combat the carrier 
status problem is to use a two-step approach that combines the NAAT with the GDH to 
determine the status (Davis et al., 2019; Mawer et al., 2019). Implementation of a two-
step process identifies those patients who have true toxigenic C. difficile and, if 
symptomatic, require treatment (Davis et al., 2019). 
Treatments and Outcomes 
The outcome for patients with C. difficile is dependent on the severity of the 
disease, the treatment, and associated risk factors including presence (Fisher & Halalau, 
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2018; Gateau, Couturier, Coia, & Barbut, 2018; Novotný et al., 2018). The treatments per 
the Infectious Disease Society of America guidelines are separated by the first episode, 
first recurrence, or subsequent recurrences along with nonsevere, severe, or fulminant 
(McDonald et al., 2018). The categorizations are standard among research experts (Cho 
et al., 2020; Crowell et al., 2017). Patients who are undertreated for C. difficile are at 
equal risk for mortality compared to those who are overtreated or appropriately treated 
(Crowell et al., 2017). Length of stay at a facility is a risk factor for increased C. difficile 
infection (Zhang et al., 2016). Length of stay remained static for inappropriately treated 
patients in the study by Crowell et al. (2017). However, a significant length of stay 
decrease was seen in appropriately treated patients (Crowell et al., 2017). Reductions in 
hospital-onset laboratory identified C. difficile cases have been recognized with a two-
step method (Block et al., 2018). However, an equal decrease has not been found in 
antibiotic prescribing (Albert, Ross, Calfee, & Simon, 2018; Davis et al., 2019). 
Although case counts have decreased, subsequent use of antibiotics has not decreased, 
which has led to poor outcomes up to and including death (Patel et al., 2017). 
Research indicated that testing methods have improved in efficiency and accuracy 
(Amado et al., 2016; Bai et al., 2017; Block et al., 2018; Brukner et al., 2019; Chang et 
al., 2019; Kamboj et al., 2018; Paitan et al., 2017). The agreement among scientists and 
professional organizations is well documented regarding the clinical manifestations of 
infection (McDonald et al., 2018; Ooijevaar et al., 2018; Reinink et al., 2017). Also, 
treatment algorithms are documented based on the disease level (Ooijevaar et al., 2018; 
Origüen et al., 2018; Simeunovic et al., 2017; Theiss et al., 2018; Truong et al., 2017). A 
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gap exists in the research related to whether the existence of clinical symptoms moderates 
the administration of antibiotic treatment based on a positive result between a two-step 
method or an NAAT that may or may not have been appropriately collected.  
Definitions 
Dependent variable: Antibiotic treatment referred to the administration or 
initiation of antibiotics used for C. difficile treatment. The antibiotics included 
vancomycin, metronidazole, and fidaxomicin. The administration or continuation of any 
of these antibiotics after testing counted as treatment (see Cho et al., 2020; Crowell et al., 
2017; Giancola, Williams, & Gentry, 2018; Ooijevaar et al., 2018).  
GDH: Glutamate dehydrogenase, which is a species-specific test used for rapid 
diagnostic testing for C. difficile (Quest Diagnostics, 2017). Most commonly used in 
conjunction with toxin assays to determine presence and toxin status together (Quest 
Diagnostics, 2017).  
Moderating variable: Symptoms referred to temperature, white blood cell count, 
or serum creatinine level. Temperature over 100.4, serum creatinine over 1.3 mg/dL, and 
white blood cell count over 15 × 109/L counted as symptoms and were marked as yes (see 
Bauer et al., 2012). Any other values in those lab values were counted as 
nonsymptomatic or no. The lab value or vital sign must have been within 24 hours before 
or after the test for C. difficile was conducted. 
NAAT: The nucleic acid amplification test, which is a rapid diagnostic test that is 
used to detect C. difficile toxin genes (Quest Diagnostics, 2017).  
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Predictor variable: Testing period for January 1 to December 31, 2015, and 
January 1 to December 31, 2018. All records during this time from patients with an 
admission who were tested for C. difficile and a positive result were included. 
Two-step method: The rapid diagnostic method used to detect toxigenic C. 
difficile in stool specimens combining the toxin assay and clostridium-specific gene 
detection with a second test performed if the results are mismatched (Johansson, 
Karlsson, & Norén, 2016; Quest Diagnostics, 2017). The GDH and toxin testing result as 
positive or negative for both the toxin and the C. difficile presence. If the GDH is 
negative and the toxin is positive, then the result is positive. If the GDH is positive but 
the toxin is negative, then another test is run as a tiebreaker (Quest Diagnostics, 2017). 
Assumptions 
I assumed that the collection of the specimens was done only if the patient 
required testing. Second, I assumed that the nursing staff accurately documented the 
temperatures. I also assumed that the knowledge regarding the testing varied by provider, 
and testing was conducted only when appropriate based on the clinician’s understanding. 
Finally, I assumed that the application of the serum creatinine or white blood cell changes 
were attributed to the probable or possible C. difficile infection and not attributed to other 
infectious processes, if present.  
Scope and Limitations 
The data set for the analysis was restricted to 2 years (2015 and 2018) in which a 
positive test result was obtained. The reasons for limiting the scope were related to the 
methodology of the project. The elimination of negative results focused the population on 
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the cases related to the research question of positive case outcomes (see Creswell & 
Creswell, 2017). Also, all extra variables were excluded from the data set, including only 
those that were used in the analysis. Restriction of the antibiotics for treatment to only 
three types (vancomycin, metradionazole, and fidaxomicin) ensured that only antibiotics 
associated with treatment for C. difficile were included. In other words, the elimination of 
other antibiotics helped to lower the level of dilution of the results (see Creswell & 
Creswell, 2017).  
One limitation of the study may have been the implementation of a strict rejection 
process for inappropriate specimens that were not in place at either time. Because the 
study focused on one facility, a limitation was potentially present for generalizing the 
results to other facilities without further research. Based on these restrictions and 
limitations, the conclusions of the study cannot be generalized to all health care facilities 
or all comparisons of testing methods.  
Summary 
C. difficile is a significant societal issue because over- or undertreatment of the 
disease impacts the overall morbidity and mortality of the population. The difference in 
testing methods was concerning due to the subsequent treatment based on the results. If 
the results are not correlated with the symptoms, then the patient may be inappropriately 
treated. The trends of hospital-onset C. difficile continue to decrease without the 
alignment of reducing antibiotic use (CDC, 2019b, 2018). One gap in the research was 
whether antibiotic treatment prescribed based on the case year via a positive test result 
was modified by the presence of recognized symptoms. Recognizing differences in 
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testing and the presence of symptoms may help with initiatives to mitigate inappropriate 
antibiotic prescriptions, which endangers the public health.   
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Section 2: Research Design and Data Collection 
The de-identified patient data records were collected on December 3 and 4, 2019, 
through the electronic medical record system as a special request from corporate clinical 
analytics. The secondary medical record set included the predictor variable of the case 
year, which also indicated the testing method as only one method was used during each 
case year. The record also included the dependent variable of antibiotic treatment and the 
moderating variable of symptoms present. The rationale for using the data was that the 
information available through the patient data records would provide an adequate sample 
that was representative of the population and would provide the necessary data points 
necessary for answering the research questions.  
Population  
The target population for the study included all patients who tested positive for C. 
difficile in 2015 or 2018 (N = 509). 
Sample Size Determination 
Although the sample size was determined based on tests conducted for C. difficile, 
a power analysis was performed using G-Power software (see Faul, Erdfelder, Buchner, 
and Lang., 2009). I assumed a two-tail test, an odds ratio of 2.25, an alpha of 0.05, and a 
minimum statistical power of 0.95. A null hypothesis probability of the dependent 
variable being equal to 1 if the independent variable was equal to 1 of 0.40 produced a 
minimum sample size of 325. The accurate a priori power analysis included an alpha 
level of .05 to reduce type I error, and power level of .95 to reduce type II error. The 
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effect size of 60% inappropriately treating was calculated based on the average for over 
or under treating (see Crowell et al., 2017). 
The data were accessed by contacting the clinical analytics team via the clinical 
services group director of infection prevention with the authority to request and share the 
data. The information included the test being conducted with a positive result on any 
patient for the case years of 2015 and 2018 and for the specified facility. The data were 
sent in an Excel file from the clinical services group infection prevention director.  
Method of Data Collection 
The data were collected by the clinical analytics team based on a positive result 
for C. difficile presence during calendar years 2015 and 2018. The data were extracted 
from electronic medical records. The standard confidentiality agreement that is signed 
each year by every staff member was maintained via the approval process for access to 
the documents through the Clinical Analytics Group. Reliability evidence was considered 
with the ability to reconstruct the data set and analysis (see Stewart & Hitchcock, 2016).  
One internal validity consideration was that historical context might have 
included other events that affected the outcomes during each case year. Another internal 
validity concern was maturation due to the possibility of changing patient types and 
prescribers during the different range of collections (see Stewart & Hitchcock, 2016). 
External validity concerns included the generalizability of the outcomes to different 
settings and treatment variations, which may be related to the timing of testing or results 




The main variables used in the analysis were clinical symptoms, case year, and 
antibiotic treatment. Each variable was introduced into the data analysis model as the 
predictor, dependent, or moderating variable. Table 1 lists all relevant variables examined 
in this analysis, followed by subsections describing the variables in detail. 
Table 1 
 






Definition Use Variable codes 
Case year Nominal Year of test Predictor 2015 or 2018 
Length of stay Ratio Length of stay for 
admission during 
which the test was 
performed 
Demographic 0-635 
Collect_location Nominal Location of test 
collection 






Symptom Nominal Presence of 
temperature, WBC, 
or serum creatinine 
above the standard 
threshold 
Moderator Yes or no 





Dependent Yes or no 
Know_Exp_Abx Nominal Known exposure 
to antibiotics 
within 30 days 
before testing 
Independent Yes or no 
Onset Nominal NHSN 
categorization of 
the organism onset 






The predictor variable was the test case year. The case year was dependent on the 
date of the C. difficile test. No calculation or modifications were made to this variable. 
The case year 2015 corresponded to the two-step method fully implemented, and the case 
year 2018 corresponded to the NAAT only. 
Dependent Variable 
The dependent variable antibiotic treatment was the administration of C. difficile 
targeted antibiotics, including vancomycin, metronidazole, and fidaxomicin (see Cho et 
al., 2020; Crowell et al., 2017; McDonald et al., 2018). Based on medication 
administration records for each patient, the date and time of antibiotic administration 
were documented. Any administration of the targeted antibiotics was coded as “yes” for 
the dependent variable indicating that the patient received antibiotic therapy after testing 
or that antibiotic therapy continued after testing if already started before testing. If no 
targeted antibiotic was administered after testing, then the antibiotic administration 
variable was coded as “no.”  
Moderator 
The moderator variable symptoms included temperature, serum creatinine, and 
white blood cell count. The temperature threshold to indicate a clinical symptom was 
greater than 100.4 Fahrenheit. The temperature of 100.5 or more was coded as “yes” for 
symptoms. Serum creatinine level above 1.3 mg/dl was coded as “yes” for a clinical 
symptom. Finally, white blood cell counts above 15 × 109/L were coded as “yes.” Fever, 
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liver abnormality, and leukocytosis (increased white blood cell count) are indicative of C. 
difficile infection (Bauer et al., 2012; McDonald et al., 2018).  
Demographic and Additional Variables 
Other data points were available for descriptive analysis, including collect 
locations to define the geographical location within the facility. Length of stay or the time 
from admitting to the collection was used to define the onset of the case per National 
Healthcare Safety Network criteria (see CDC, 2020). Community onset included cases 
identified within the first 3 days of admission, and the rest were hospital-onset cases (see 
CDC, 2020). The length of stay was a continuous variable. Finally, known exposure to 
antibiotics within 30 days before the case identification indicated the significant risk for 
the development of C. difficile infection (Lee et al., 2019). 
Statistical Design 
IBM SPSS Statistics Version 25 was used for the data analysis of this study. The 
data set was downloaded in Excel and cleaned in IBM SPSS Statistics Version 25. The 
file was provided in an Excel format containing 509 records. Each record was thoroughly 
reviewed for missing data or inconsistencies. No data records had missing information. 
Variables not needed in the analysis were removed from the data set.  
Binary logistic regression was chosen for statistical analysis, including variables 
from both research questions. Binary logistic regression assumptions were met with a 
dichotomous dependent variable (antibiotic treatment), nominal independent variables 
(case year and symptoms), and independence of observations (see Lund Research Ltd., 
2018). Frequency tables were included for descriptive analysis of additional variables 
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(length of stay, known exposure to antibiotics, and onset). In the binary logistic 
regression, the probability cut value of 0.5 was used to determine the appropriate 
classification (see Lund Research Ltd., 2018). The Wald test was used to identify 
variables that had a significant effect at or above a p value of 0.5.  
Research Questions 
RQ1: Is there a statistically significant association between the testing period 
(2015 and 2018) and antibiotic treatment (yes or no)? 
Ho1: There is not a statistically significant association between the testing period 
(2015 and 2018) and antibiotic treatment (yes or no). 
Ha1: There is a statistically significant association between the testing period 
(2015 and 2018) and antibiotic treatment (yes or no). 
RQ2: Does the presence of a recognized symptom (yes or no) moderate the 
relationship between the testing period (2015 and 2018) and antibiotic treatment (yes or 
no)? 
Ho2: The presence of a recognized symptom does not moderate the relationship 
between the testing period (2015 and 2018) and antibiotic treatment (yes or no). 
Ha2: The presence of a recognized symptom moderates the relationship between 
the testing period (2015 and 2018) and antibiotic treatment (yes or no). 
Threats to Validity 
Historical internal validity was addressed by confirming the process change dates 
for the C. difficile testing processes and policies (see Stewart & Hitchcock, 2016). The 
laboratory department and infection prevention department personnel who are 
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responsible for changes to the C. difficile testing processes confirmed no other historical 
changes occurred during the two study years. Although no changes occurred in the 
process, the medical staff and patients were continuously changing. New staff learning 
the processes can lead to errors. However, the same continuous education was given 
throughout each case year. No correction for this issue was available.  
External validity consideration for the timing of testing and resultant antibiotic 
prescriptions must be considered for generalization because an inpatient facility has staff 
24 hours a day to result and prescribe where other facilities may not (see Stewart & 
Hitchcock, 2016). This leads to a generalizing issue based on the location where testing 
takes place because the current project was set only for an inpatient acute care facility. 
The findings may not be applicable to long-term care facilities or outpatient settings.  
Ethical Considerations 
A facility-based institutional review board application was completed and 
approved before study implementation. Data access to the secondary data set required 
permission via an email from the clinical services group infection prevention director, 
who requested the data on my behalf. Confidentiality, honesty, and integrity in all data 
gathering, storage, and use were consistently maintained even though the data set was a 
secondary data set that did require primary subject contact. All data will be kept secured 
via password protection for at least 5 years.  
Summary 
Section 2 included the details regarding the study methodology. The assessment 
included the statistical testing plan for the case year predicting the antibiotic treatment. 
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The influence of a C. difficile symptom presence was assessed. Also, the onset 
categorization, collect location, and length of stay were included in the assessment. 
Validity, reliability, and ethical considerations were reviewed. The study results are 




Section 3: Results and Findings 
I examined the influence of symptoms indicative of C. difficile among two 
different case years in which a different testing method was employed each year. The 
antibiotic-prescribing behavior of the physician was the dependent or outcome variable. 
The study addressed the relationship between testing period, antibiotic treatment, and 
presence of symptoms indicative of C. difficile infection. This section includes the 
quantitative analysis, results, and interpretation of the results. 
Data Collection of Secondary Data Set 
The data included in this study originated from electronic medical records from a 
large suburban health care facility with over 500 beds. A single data set included the two 
years selected for analysis, 2015 and 2018. Discrepancy concerns included possible 
missing data values, incorrect reporting of values, or potential bias. Bias was minimized 
through the inclusion of objective variables based on test results. No missing data values 
were identified in the data set. The potential for incorrect reporting, although not 
eliminated, was minimized because the methods for reporting the test results, symptoms, 
and descriptive values are standardized throughout the hospital based on standard policy 
and procedure. The data set review included quality and validity assurance with no issues 
identified. 
Descriptive Statistics 
The demographic population included a total sample size of 509 patients with the 
inclusion of both 2015 and 2018 cases. The G*Power analysis resulted in a minimum 
sample size of 325 with odds ratio = 2.25, alpha = 0.05, power = 0.95, and 
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implementation of a priori. Table 2 includes results of the analysis conducted for the 
length of stay to obtain mean, median, standard error of deviation, minimum, and 
maximum values. Table 3 includes the results of the analysis for frequency and test for 
proportions as the remainder of the variables were categorical and discrete in nature. No 
data values were excluded.  
Table 2 
 








2015 22.31 11.00 2.675 0 635 




Descriptive Analysis for Categorical Variables 
Variable Category Case Year 2015 Case Year 2018 
Frequency Percentage Frequency Percentage 
Collect location Adult ER 23 6.6 17 10.4 
 Adult inpatient 276 79.8 123 75.5 
 Adult outpatient 0 0 12 7.4 
 Pediatric ER 11 3.2 7 4.3 
 Pediatric inpatient 36 10.4 4 2.5 
Symptom Yes 190 54.9 109 66.9 
Abx_administered Yes 287 82.9 147 90.2 
Know_Exp_Abx Yes 212 61.3 124 76.1 
Onset Hospital onset 151 43.6 80 49.1 
 Community onset 195 56.4 83 50.9 
 
Analysis of Hypothesis 
Research Question 1  
RQ1: Is there a statistically significant association between the testing period 
(2015 and 2018) and antibiotic treatment (yes or no)? 
28 
 
Ho1: There is not a statistically significant association between the testing period 
(2015 and 2018) and antibiotic treatment (yes or no). 
Ha1: There is a statistically significant association between the testing period 
(2015 and 2018) and antibiotic treatment (yes or no). 
Binomial logistic regression was performed to determine whether a relationship 
existed between the testing period and antibiotic treatment. The logistic regression model 
was statistically significant, χ2(1) = 4.91, p < .05. The model explained 1.7% 
(Nagelkerke R2) of the variance in antibiotic treatment and correctly classified 85.3% of 
cases. Sensitivity was 100%, and specificity was 0%. The predictor variable case year 
was statistically significant and shown to contribute to the model with the year 2015 set 
as the reference (see Table 4). Patients in the case year 2018 had 1.889 times higher odds 
of having antibiotic treatment than patients in the case year 2015. The unstandardized 
Beta weight for the predictor variable 2018: B = [0.636], Wald = [4.506], p = .034. In 




Binary Logistic Regression: Case Year 
Variables B Wald Exp(B) 95% C.I for EXP(B) Sig 
Lower Upper 





Research Question 2  
RQ2: Does the presence of a recognized symptom (yes or no) moderate the 
relationship between the testing period (2015 and 2018) and antibiotic treatment (yes or 
no)? 
Ho2: The presence of a recognized symptom does not moderate the relationship 
between the testing period (2015 and 2018) and antibiotic treatment (yes or no). 
Ha2: The presence of a recognized symptom moderates the relationship between 
the testing period (2015 and 2018) and antibiotic treatment (yes or no). 
Binomial logistic regression was performed to determine whether the relationship 
between the testing period and antibiotic treatment was moderated by the presence of 
symptoms. The logistic regression model was statistically significant, χ2(2) = 5.998, p < 
.05. The model explained 2.1% (Nagelkerke R2) of the variance in antibiotic treatment 
and correctly classified 85.3% of cases. Sensitivity was 100%, and specificity was 0%. 
The predictor variable case year was statistically significant (see Table 5) with “2015” set 
as the reference, and was not statistically significant with “No” set as the reference. 
Patients in the case year 2018 had 1.831 times higher odds of having antibiotic treatment 
than patients in the case year 2015 with the symptom moderating at 1.303 higher odds 
ratio. The adjusted unstandardized Beta weight for the predictor variable 2018: B = 
[0.605], Wald = [4.032], p = .045. In 2018, the odds ratio increased by 83% [Exp (B) = 
1.831, 95% CI (1.015, 3.304)] for antibiotic treatment when accounting for the Symptom 





Binary Logistic Regression: Case Year With Symptom Moderator Adjusted  
Variables B Wald Exp(B) 95% C.I for EXP(B) Sig 
Lower Upper 
Case year .605 4.032 1.831 1.015 3.304 .045 
Symptom .265 1.093 1.303 .793 2.140 .296 
 
Summary 
Before statistical analysis, all variables were validated and recoded. Descriptive 
summaries with frequency and percentage were completed for all categorical variables. 
Binary logistic regression was conducted for the two research questions. The alternative 
hypothesis was accepted with statistical significance for the case year and antibiotic 
treatment association. Therefore, there was a significant association between the case 
year and antibiotic treatment. However, for the second research question, the null 
hypothesis was accepted because no statistically significant association between case year 
and antibiotic treatment with the moderating effect of the symptom presence existed. The 
key findings, social change implications, and application to professional practice are 




Section 4: Application to Professional Practice and Implications for Social Change 
The aim of the study was to determine whether an association exists between the 
type of C. difficile testing based on case year and antibiotic treatment in a large hospital 
population. The secondary aim was to determine whether the presence of known C. 
difficile symptoms moderated the relationship between case year and antibiotic treatment. 
Death related to C. difficile incidence in the United States equaled approximately 70 per 
1,000 infections in 2019 (14,000 deaths / 200,000 infections) (CDC, 2019a). The study 
findings indicated whether a significant relationship exists between testing type based on 
case year, antibiotic treatment and presence of C. difficile symptoms.  
Key Findings 
Case Year and Antibiotic Treatment  
The case year was aligned with the type of test that was conducted on the group. 
The NAAT was conducted in 2015, and GDH with Toxin was conducted in 2018. The 
total case counts decreased by 51%; there were 346 cases in 2015 and 169 cases in 2018. 
The decrease in testing from NAAT to GDH with Toxin is congruent with the literature 
related to the efficiency of turnaround time (see Davis et al., 2019). The antibiotic 
treatment percentage decreased by 8% from 90% in 2015 to 82% in 2018. The 
combination of a large decrease in case counts with minimal decrease in antibiotic 
treatment is congruent with current literature (see Albert et al., 2018; Davis et al., 2019). 
The odds ratio of antibiotic treatment for C. difficile was 1.889 times higher in 2018 
compared to 2015. The results increase the discipline clarity that GDH with Toxin testing 
compared with NAAT was associated with higher antibiotic treatment odds.  
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Case Year, Antibiotic Treatment, and Symptoms  
The presence of at least one clinical symptom (white blood cell count increase, 
fever, or serum creatinine increase) increased by 12% from 2015 (54.9%) to 2018 
(66.9%). The increase indicates that the physicians may have been focusing more on the 
agreed-upon criteria for testing, as evidenced in the literature (see Bauer et al., 2012; 
McDonald et al., 2018). The addition of a moderator of clinical symptoms to the 
relationship of case year and antibiotic treatment did not result in a statistically 
significant association. The odds of the existence of the moderator (symptoms) with 
antibiotic treatment was 30%. However, the addition of the moderator had only a 6% 
change in odds for the case year and antibiotic treatment relationship with a resultant 
83% higher odds of antibiotic treatment in 2018 compared to 2015. Therefore, the 
presence of one or more symptoms known to be clinically relevant did not affect the 
testing type and antibiotic treatment relationship.  
Known Exposure to Antibiotics and Length of Stay  
Two risks of developing C. difficile infection are known exposure to antibiotics 
and length of stay in a facility (Lee et al., 2019; Zhang et al., 2016). The length of stay for 
patients with positive C. difficile results in 2015 averaged 22.31 days and decreased to 
19.37 days in 2018. The mean length of stay was at the top of the acceptable average 
range for C. difficile infection and slightly under in 2018 (Zhang et al., 2016). Crowell et 
al. (2017) suggested that one possible reason for the decrease may be that the antibiotic 
treatment may have been appropriately applied. Patients taking third-generation 
cephalosporins within 3 days before the positive test increased by approximately 15% 
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from 2015 (61.3%) to 2018 (76.1%). Both case years of C. difficile infections showed 
rates of previous exposure to antibiotics above 50%, which aligns with the research (Lee 
et al., 2019).  
Collect Location and Onset 
The collect location was included as a demographic variable to address validity 
concerns (see Stewart & Hitchcock, 2016). The collect location includes the general age 
of the patient (pediatric versus adult) and inpatient or outpatient. The highest number of 
samples collected in 2015 equaled 79.8% in an adult inpatient location and decreased by 
4.3% in 2018. Pediatric inpatient specimens were second highest in 2015 with 10.4% and 
2.5% in 2018. The total pediatric location samples equaled 13.6% in 2015 and half the 
amount in 2018 at 6.7%. The total adult location samples were higher by 8% in 2018 
(93.3%) compared to 2015 (86.4%). Combined outpatient or ER samples were double the 
amount in 2018 (22.1%) compared to 2015 (9.8%). Finally, overall inpatient samples 
showed a difference of 27.7% between 2015 (90.2%) and 2018 (77.9%).  
The collection location is one of the criteria used to determine the onset category 
of community-onset or hospital-onset. The hospital-onset rate of C. difficile infections in 
the United States in 2017 was approximately 50% (CDC, 2019a, 2019b, 2020). The 
hospital-onset rate in 2015 was 6.4% below the 2017 U.S. rate and was less than 1% 
below the rate in 2018, indicating that the hospital rates are in line with the existing 
literature (CDC, 2019a, 2019b, 2020). Facility administrators are financially incentivized 
to have the lowest possible count of hospital-onset cases, and the percentage is moving in 
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the wrong direction (Medicare Program Hospital Inpatient Prospective Payment Systems 
for Acute Care Hospitals, 2017). 
Alignment With the Theoretical Framework 
The symbolic interaction theory refers to patient treatment as a result of 
interactions between the physician (actor) and the hospital (world; Goffman, 1967). The 
interactions between the physician, patient, and test findings initiate the decision-making 
process as part of symbolic interaction theory (Bobenchik, 2019; Goffman, 1967; Rose, 
1962). Physicians require ample knowledge regarding the application of test results, 
clinical manifestation of illness, and appropriate treatment options that come from 
multiple different interactions (CDC, 2019c). The physician considers the presence of 
symptoms, test results, and antibiotic treatment options while weighing the potential of 
over- or undertreating, which may lead to outcomes that cause harm or even death 
(Crowell et al., 2017; Patel et al., 2017). 
Limitations of the Study 
The generalizability of the data was a limitation. The data were limited to a single 
acute care facility with more than 500 beds in a suburban location. Another limitation 
related to the location was the availability of services such as physician call, pharmacy 
interaction, and size of the physician group. The differences in size, services, and type of 
facility limited the generalizability of the data (see Stewart & Hitchcock, 2016). The 
results are not generalizable to different size facilities or types (e.g., rehabilitation, long-
term care facilities, or outpatient settings). The validity and reliability of data were 




This study focused on the moderating effect of recognized symptoms on the 
relationship of a change from NAAT to GDH/Toxin testing and antibiotic treatments. 
The study findings indicated that the presence of symptoms did not significantly affect 
the treatment being applied. Research exists related to appropriate treatment of C. difficile 
based on the level of disease severity (McDonald et al., 2018). Further study of the 
choices of antibiotic treatment based on the level of severity of illness with the identified 
change in the testing method should be conducted. The additional research will provide 
the opportunity to explore the association between testing methods, antibiotic treatment, 
and severity of illness. An investigation into different facility sizes and types may help to 
expand the generalizability of the current findings. Facilities of similar size and type may 
apply the epidemiological findings from this study.  
Implications for Professional Practice and Social Change 
The study finding that symptoms did not moderate the antibiotic treatment 
prescribing patterns indicates a potential antimicrobial stewardship concern. The potential 
for increased severity in illness or antibiotic-resistant organisms stems from inappropriate 
antibiotic use (Isaac et al., 2016). Successful treatment of C. difficile infection requires 
multiple interactions (communicative, symbolic, physical) between the physician, patient, 
and other medical staff leading to learned behavioral outcomes in the form of diagnosis 
and treatment led by the physician (Bobenchik, 2019; Goffman, 1967; Rose, 1962).  
One professional practice recommendation is to include the severity of illness 
with documented symptoms as criteria for antibiotic therapy. The physician group has the 
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potential to agree upon an approved treatment algorithm. The treatment algorithm also 
addresses the community level. Many of the physicians work in multiple facilities, which 
allows for the physician’s experience to spread the policy through interactions. 
Organizationally, continued appropriate testing with the presence of clinical symptoms, 
as found in the current study, supports the financial incentives by lowering the hospital-
onset cases (see Medicare Program Hospital Inpatient Prospective Payment Systems for 
Acute Care Hospitals, 2017). Finally, the societal impact is in the potential reduction in 
global antibiotic-resistant organisms, C. difficile infection, and C. difficile death in the 
United States (see CDC, 2019c; Colman et al., 2019; Isaac et al., 2017; McCullough et 
al., 2015). 
Conclusion 
An examination of the association between testing method (case year), antibiotic 
treatment post testing, and the presence of symptoms indicated that the presence of 
symptoms (or lack of symptoms) did not change the relationship between testing method 
and treatment for C. difficile positive patients. C. difficile has the potential for mortality if 
not identified correctly and not treated in a timely or appropriate manner. Overtreatment 
and undertreatment of C. difficile are crucial for physicians to monitor. The addition of an 
improved algorithm with clinical symptoms and severity of illness defined may help 
physicians protect patients from unintended harm. The implementation of the improved 
algorithm and policy across the organization for the medical staff and clinical staff may 
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